Format

Send to

Choose Destination
Leukemia. 2015 Jun;29(6):1390-401. doi: 10.1038/leu.2014.347. Epub 2014 Dec 23.

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Author information

1
1] Department of Control and Computer Engineering, Politecnico di Torino, Turin, Italy [2] Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA [3] Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
2
Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy.
3
Department of Human Genetics, KU Leuven, Leuven, Belgium.
4
1] Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy [2] Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
5
Translational Cell and Tissue Research, KU Leuven, Department of Pathology, UZ Leuven, Leuven, Belgium.
6
Department of Control and Computer Engineering, Politecnico di Torino, Turin, Italy.
7
Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
8
Pathology & Lymphoid Malignancies Units, San Raffaele Scientific Institute, Milan, Italy.
9
Molecular Imaging Center, Department of Chemistry IFM and Molecular Imaging Center, University of Torino, Turin, Italy.
10
Teva Pharmaceuticals, Inc, North Wales, PA, USA.
11
Institute of Hematology and Medical Oncology L. and A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
12
Institute of Hematology, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, Perugia, Italy.
13
Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
14
The Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
15
Department of Pathology, City of Hope Medical Center, Duarte, CA, USA.
16
The Jackson Laboratory, Bar Harbor, ME, USA.
17
1] Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland [2] IDSIA Dalle Molle Institute for Artificial Intelligence, Manno, Switzerland [3] SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
18
1] Department of Control and Computer Engineering, Politecnico di Torino, Turin, Italy [2] Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA.
19
Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA.
20
1] Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland [2] Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
21
1] Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy [2] Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA [3] Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.

Abstract

Although anaplastic large-cell lymphomas (ALCL) carrying anaplastic lymphoma kinase (ALK) have a relatively good prognosis, aggressive forms exist. We have identified a novel translocation, causing the fusion of the TRAF1 and ALK genes, in one patient who presented with a leukemic ALK+ ALCL (ALCL-11). To uncover the mechanisms leading to high-grade ALCL, we developed a human patient-derived tumorgraft (hPDT) line. Molecular characterization of primary and PDT cells demonstrated the activation of ALK and nuclear factor kB (NFkB) pathways. Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expansion of lymphoma cells, lacking PRDM1/Blimp1 and carrying c-MYC gene amplification. The treatment with proteasome inhibitors of TRAF1-ALK cells led to the downregulation of p50/p52 and lymphoma growth inhibition. Moreover, a NFkB gene set classifier stratified ALCL in distinct subsets with different clinical outcome. Although a selective ALK inhibitor (CEP28122) resulted in a significant clinical response of hPDT mice, nevertheless the disease could not be eradicated. These data indicate that the activation of NFkB signaling contributes to the neoplastic phenotype of TRAF1-ALK ALCL. ALCL hPDTs are invaluable tools to validate the role of druggable molecules, predict therapeutic responses and implement patient specific therapies.

PMID:
25533804
PMCID:
PMC4864432
DOI:
10.1038/leu.2014.347
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center